816 results on '"Nuciforo, Paolo"'
Search Results
2. Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients
3. A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?
4. RAGE/SNAIL1 signaling drives epithelial-mesenchymal plasticity in metastatic triple-negative breast cancer
5. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor–stroma ratio in colon cancer
6. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
7. DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype
8. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
9. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer
10. Evaluation of homologous recombination repair (HRR) status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays.
11. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
12. Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
13. pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation
14. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer
15. Histology-informed liver diffusion MRI: biophysical model design and demonstration in cancer immunotherapy
16. Results from the UNITED study: a multicenter study validating the prognostic effect of the tumor–stroma ratio in colon cancer
17. Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer
18. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer
19. LOXL2‐mediated chromatin compaction is required to maintain the oncogenic properties of triple‐negative breast cancer cells.
20. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer
21. Evaluation of homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays
22. Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer
23. FIGURE 4 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression
24. Weakly supervised deep learning predicts immunotherapy response in solid tumors based on PD-L1 expression
25. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
26. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
27. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment
28. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
29. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
30. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer
31. Figure S3 from Early-Stage Breast Cancer Detection in Breast Milk
32. Data from Early-Stage Breast Cancer Detection in Breast Milk
33. Early-Stage Breast Cancer Detection in Breast Milk
34. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
35. Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients
36. Impact of the COVID-19 pandemic in the early-onset colorectal cancer
37. First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours
38. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
39. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
40. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence
41. Data from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
42. Supplementary Figure S2 from Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
43. Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
44. Supplementary Table S1 from Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
45. Data from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
46. Data from Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
47. Supplementary Data from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
48. Supplementary Figure from A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
49. Supplementary Table 1 from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
50. Supplementary Data from Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.